A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors

Epidermal Growth Factor Receptor (EGFR) activates a robust signalling network to which colon cancer tumours often become addicted. Cetuximab, one of the monoclonal antibodies targeting this pathway, is employed to treat patients with colorectal cancer. However, many patients are intrinsically refrac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2016-11, Vol.7 (44), p.72167-72183
Hauptverfasser:	Gelfo, Valerio, Rodia, Maria Teresa, Pucci, Michela, Dall'Ora, Massimiliano, Santi, Spartaco, Solmi, Rossella, Roth, Lee, Lindzen, Moshit, Bonafè, Massimiliano, Bertotti, Andrea, Caramelli, Elisabetta, Lollini, Pier-Luigi, Trusolino, Livio, Yarden, Yosef, D'Uva, Gabriele, Lauriola, Mattia
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Caco-2 Cells Cell Culture Techniques Cell Proliferation - drug effects Cetuximab - pharmacology Cetuximab - therapeutic use Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Drug Resistance, Neoplasm ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Humans Interleukin-1alpha - metabolism Interleukin-1beta - metabolism Interleukin-8 - metabolism Microscopy, Confocal Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Research Paper Signal Transduction - drug effects Spheroids, Cellular - metabolism Up-Regulation Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!